App-Quantinova.ai

Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Jennifer J. Knox - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Gemcitabine

A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.

Shubham Pant - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Gemcitabine

A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).

Andrew L. Coveler - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

Access to innovative cancer medicines in gastrointestinal oncology: 2010 through 2020.

David Edward O Reilly - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastrointestinal stromal tumor

N/A

Body weight loss (BWL) as a prognostic/predictive factor in previously treated patients (pts) with metastatic gastric or gastroesophageal junction cancer (mGC/GEJC): Post-hoc analyses of the phase III tags trial.

Michele Ghidini - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

N/A

Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.

Jessica Howell - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

Sorafenib

The impact of changes in service delivery in patients with colorectal cancer during the first peak of the COVID-19 pandemic.

Konstantinos Kamposioras - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Colorectal Cancer

N/A

COVID-19 infection in gastrointestinal (GI) cancer patients receiving systemic anticancer treatment (SACT) during the outbreak of the pandemic: The Guy's Cancer Centre experience.

Eirini Tsotra - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

Bruno Sangro - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Ipilimumab

Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial.

Christopher Williams - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

amphiregulin

Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study.

Josep Tabernero - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Tipiracil and trifluridine

A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).

Yelena Y. Janjigian - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Adrucil injection

Role of ctDNA to predict risk of recurrence following potentially curative resection of biliary tract and pancreatic malignancies.

Angela Lamarca - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer.

Azim Jalali - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

TAS102

Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.

Julien Taieb - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

Molecular profiling of advanced pancreatic ductal adenocarcinoma (PDAC): Role of ctDNA.

Angela Lamarca - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

Methadone hydrochloride

The Efficacy of Pharmacological Intervention for Reducing Macrovesicular Lipid Accumulation in Primary Human Hepatocytes In Vitro: A Precursor Study to Improvement of Macrovesicular Steatosis in Donor Livers with Normothermic Machine Perfusion of the Liver

Yuri L. Boteon - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Blood and Graft Biomarkers Predictive of Operational Tolerance in Liver Transplant Recipients on Sirolimus

Josh Levitsky - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Rapacan

Calmangafodipir is a new treatment for late stage liver toxicity after acetaminophen overdose

James W. Dear - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fulminant hepatic failure

Superoxide dismutase

Pre‐Transplant Performance Status and Outcome of Liver Transplantation.

William Bernal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts